Global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Market Growth 2025-2031
Description
The global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market size is predicted to grow from US$ 420 million in 2025 to US$ 513 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is a preventive biological product developed to protect pigs, particularly swine in the agricultural industry, from the PRRS virus. PRRS is a significant disease affecting pigs, causing reproductive issues in sows and respiratory problems in young and growing pigs. The vaccine is designed to stimulate the pig's immune system to recognize and defend against the PRRS virus, reducing the severity of the disease's impact and preventing its transmission within swine populations.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
LP Information, Inc. (LPI) ' newest research report, the “Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Forecast” looks at past sales and reviews total world Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales for 2025 through 2031. With Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) industry.
This Insight Report provides a comprehensive analysis of the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS).
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Live Vaccine
Inactivated Vaccine
Segmentation by Application:
Government Tender
Marketing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
Key Questions Addressed in this Report
What is the 10-year outlook for the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market?
What factors are driving Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market opportunities vary by end market size?
How does Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) is a preventive biological product developed to protect pigs, particularly swine in the agricultural industry, from the PRRS virus. PRRS is a significant disease affecting pigs, causing reproductive issues in sows and respiratory problems in young and growing pigs. The vaccine is designed to stimulate the pig's immune system to recognize and defend against the PRRS virus, reducing the severity of the disease's impact and preventing its transmission within swine populations.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
LP Information, Inc. (LPI) ' newest research report, the “Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) Industry Forecast” looks at past sales and reviews total world Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales for 2025 through 2031. With Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) industry.
This Insight Report provides a comprehensive analysis of the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS).
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Live Vaccine
Inactivated Vaccine
Segmentation by Application:
Government Tender
Marketing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
Key Questions Addressed in this Report
What is the 10-year outlook for the global Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market?
What factors are driving Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) market opportunities vary by end market size?
How does Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
127 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
